Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
BDTX - Black Diamond Therapeutics, Inc
Market Cap 179.78M P/E - EPS this Y 26.10% Ern Qtrly Grth -
Income -80.55M Forward P/E -1.88 EPS next Y -5.80% 50D Avg Chg 5.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 50.00%
Dividend N/A Price/Book 1.30 EPS next 5Y - 52W High Chg -49.00%
Recommedations 1.60 Quick Ratio 6.67 Shares Outstanding 56.50M 52W Low Chg 196.00%
Insider Own 2.27% ROA -40.41% Shares Float 44.48M Beta 2.49
Inst Own 95.24% ROE -83.38% Shares Shorted/Prior 5.86M/6.01M Price 3.49
Gross Margin - Profit Margin - Avg. Volume 4,257,912 Target Price 14.83
Oper. Margin - Earnings Date Nov 4 Volume 369,175 Change -5.68%
Healthcare | Biotechnology | United States
About Black Diamond Therapeutics, Inc

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Black Diamond Therapeutics, Inc News
12/12/24 US Penny Stocks Spotlight: Information Services Group Among 3 Top Picks
11/05/24 Black Diamond: Q3 Earnings Snapshot
11/05/24 Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks
11/05/24 Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/01/24 Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
10/07/24 Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
09/23/24 Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
09/23/24 Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
09/22/24 Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
09/14/24 Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
08/08/24 Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
08/08/24 All You Need to Know About Black Diamond (BDTX) Rating Upgrade to Buy
08/06/24 Black Diamond: Q2 Earnings Snapshot
08/06/24 Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
07/02/24 Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?
07:28 PM Is Black Diamond Therapeutics, Inc. (BDTX) a Good Biotech Penny Stock to Buy Right Now?
06/01/24 Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
07:00 AM Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
05/22/24 Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is favoured by institutional owners who hold 60% of the company
05/10/24 Should You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings?
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Behbahani Ali Director Director Jul 05 Buy 5.00 1,000,000 5,000,000 4,448,757 07/06/23
BIOTECH GROWTH N V 10% Owner 10% Owner Jun 27 Buy 5.4914 1,740,000 9,555,036 7,117,839 06/29/23
BIOTECH GROWTH N V 10% Owner 10% Owner Oct 27 Buy 2.03 364,652 740,244 5,278,038 10/31/22
BIOTECH GROWTH N V 10% Owner 10% Owner Apr 18 Buy 3.27 300,000 981,000 4,288,402 04/20/22
BIOTECH GROWTH N V 10% Owner 10% Owner Apr 12 Buy 3.5 252,556 883,946 3,988,402 04/14/22
Hatzis-Schoch Brent See Remarks See Remarks Apr 13 Option 3.2 4,078 13,050 12,478 04/13/21
Hatzis-Schoch Brent See Remarks See Remarks Apr 13 Sell 25 4,078 101,950 8,400 04/13/21
Roberts Christopher D. Chief Scientific Off.. Chief Scientific Officer Mar 04 Option 10.86 2,500 27,150 5,700 03/04/21
Roberts Christopher D. Chief Scientific Off.. Chief Scientific Officer Mar 04 Sell 26.21 2,500 65,525 3,200 03/04/21
Hatzis-Schoch Brent See Remarks See Remarks Feb 12 Sell 27.43 4,078 111,860 8,400 02/12/21
Hatzis-Schoch Brent See Remarks See Remarks Feb 12 Option 3.2 4,078 13,050 12,478 02/12/21
Roberts Christopher D. Chief Scientific Off.. Chief Scientific Officer Feb 04 Option 10.86 2,500 27,150 5,700 02/04/21
Roberts Christopher D. Chief Scientific Off.. Chief Scientific Officer Feb 04 Sell 25.35 2,500 63,375 3,200 02/04/21
Hatzis-Schoch Brent See Remarks See Remarks Jan 14 Option 7.03 11,578 81,393 19,978 01/14/21
Hatzis-Schoch Brent See Remarks See Remarks Jan 14 Sell 32.49 11,578 376,169 8,400 01/14/21
Leggett Thomas Chief Financial Offi.. Chief Financial Officer Jan 11 Option 10.86 3,000 32,580 3,000 01/11/21
Leggett Thomas Chief Financial Offi.. Chief Financial Officer Jan 11 Sell 33.94 3,000 101,820 01/11/21
Roberts Christopher D. Chief Scientific Off.. Chief Scientific Officer Jan 06 Option 10.86 2,500 27,150 5,700 01/06/21
Roberts Christopher D. Chief Scientific Off.. Chief Scientific Officer Jan 06 Sell 31.54 2,500 78,850 3,200 01/06/21
Epstein David M. See Remarks See Remarks Jan 06 Option 6.42 3,000 19,260 708,423 01/06/21
Epstein David M. See Remarks See Remarks Jan 06 Sell 31.39 12,000 376,680 696,423 01/06/21
Bolzon Bradley J PhD Director Director Dec 01 Sell 33.65 10,393 349,724 874,099 12/01/20
Bolzon Bradley J PhD Director Director Nov 23 Sell 33.01 130,017 4,291,861 4,818,600 11/23/20
Bolzon Bradley J PhD Director Director Nov 19 Sell 33.07 4,730 156,421 4,933,454 11/19/20
Bolzon Bradley J PhD Director Director Nov 17 Sell 33.62 4,700 158,014 4,937,632 11/17/20
Bolzon Bradley J PhD Director Director Nov 13 Sell 34.34 15,598 535,635 4,941,784 11/13/20
Bolzon Bradley J PhD Director Director Nov 12 Sell 34.1 39,583 1,349,780 5,646,377 11/12/20
Bolzon Bradley J PhD Director Director Nov 10 Sell 33.09 9,400 311,046 5,681,344 11/10/20
Bolzon Bradley J PhD Director Director Nov 06 Sell 33.14 11,348 376,073 5,689,647 11/06/20
Roberts Christopher D. Chief Scientific Off.. Chief Scientific Officer Nov 04 Option 10.86 2,500 27,150 2,500 11/04/20
Roberts Christopher D. Chief Scientific Off.. Chief Scientific Officer Nov 04 Sell 31.95 2,500 79,875 11/04/20
Epstein David M. See Remarks See Remarks Nov 03 Sell 31.5 12,000 378,000 711,923 11/03/20
Epstein David M. See Remarks See Remarks Nov 03 Option 6.42 3,000 19,260 723,923 11/03/20
Bolzon Bradley J PhD Director Director Oct 28 Sell 33.17 8,903 295,313 5,699,671 10/28/20
Bolzon Bradley J PhD Director Director Oct 20 Sell 33.35 15,746 525,129 5,707,536 10/20/20
Bolzon Bradley J PhD Director Director Oct 15 Sell 33.24 17,240 573,058 5,721,445 10/15/20
Bolzon Bradley J PhD Director Director Oct 13 Sell 33.43 22,625 756,354 5,736,674 10/13/20
Bolzon Bradley J PhD Director Director Oct 08 Sell 33.41 45,926 1,534,388 5,756,660 10/08/20
Hatzis-Schoch Brent See Remarks See Remarks Sep 16 Option 3.2 4,078 13,050 7,078 09/16/20
Hatzis-Schoch Brent See Remarks See Remarks Sep 16 Sell 31.58 4,078 128,783 3,000 09/16/20
Leggett Thomas Chief Financial Offi.. Chief Financial Officer Sep 16 Option 10.86 3,000 32,580 3,000 09/16/20
Leggett Thomas Chief Financial Offi.. Chief Financial Officer Sep 16 Sell 31 3,000 93,000 09/16/20